No increased mortality in patients with rheumatoid arthritis treated with biologics: results from the biologics register of six rheumatology institutes in Japan

REFERENCES

• Allebeck P. Increased mortality in rheumatoid arthritis. Scand J Rheumatol. 1982;11:81–6.
   PubMed Web of Science ®Google Scholar
• Pincus T, Brooks RH, Callahan LF. Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. Ann Intern Med. 1994;120:26–34.
   Google Scholar
• Symmons DP, Jones MA, Scott DL, Prior P. Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol. 1998;25:1072–7.
   PubMed Web of Science ®Google Scholar
• Bjomadal L, Baecklund E, Yin L, Granath F, Klareskog L, Ek-bom A. Decreasing mortality in patients with rheumatoid arthri-tis: results from a large population based cohort in Sweden, 1964–95. J Rheumatol. 2002;29: 906–12.
   Google Scholar
• Book C, Saxne T, Jacobsson LT. Prediction of mortality in rheumatoid arthritis based on disease activity markers. J Rheu-matol. 2005;32:430–4.
   Google Scholar
• Young A, Koduri G, Batley M, Kufinskaya E, Gough A, Norton S, et al. Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology (Oxford). 2007;46:350–7.
   Google Scholar
• Nakajima A, Inoue E, Tanaka E, Singh G, Sato E, Hoshi D, et al. Mortality and cause of death in Japanese patients with rheuma-toid arthritis based on a large observational cohort, IORRA. Scand J Rheumatol. 2010;39:360–7.
   PubMed Web of Science ®Google Scholar
• Jacobsson LT, Turesson C, Nilsson JA, Petersson IF, Lindqvist E, Saxne T, et al. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66: 670–5.
   PubMed Web of Science ®Google Scholar
• Naranjo A, Sokka T, Descalzo MA, Calvo-Alen J, Horslev-Pet-ersen K, Luukkainen RK, et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther. 2008;10:R30.
   Google Scholar
• Dixon WG, Watson KD, Lunt M, Hyrich KL, BSfRBRCC Consortium, Silman A, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor a therapy. Arthritis Rheum. 2007;56:2905–12.
   PubMed Web of Science ®Google Scholar
• Greenberg JD, Kremer JM, Curtis JR, Hochberg MC, Reed G, Tsao P, et al. Tumour necrosis factor antagonist use and associ-ated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70:576–82.
   PubMed Web of Science ®Google Scholar
• Carmona L, Descalzo MA, Perez-Pampin E, Ruiz-Montesinos D, Erra A, Cobo T, et al. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis. 2007;66:880–5.
   Google Scholar
• Lunt M, Watson KD, Dixon WG, Symmons DP, Hyrich KL. No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2010;62:3145–53.
   Google Scholar
• Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275–85.
   PubMed Web of Science ®Google Scholar
• Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustia-nowski AP, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheuma-tology (Oxford). 2011;50: 124–31.
   Google Scholar
• Suzuki A, Ohosone Y, Obana M, Mita S, Matsuoka Y, Irimajiri S. Cause of death in 81 autopsied patients with rheumatoid arthritis. J Rheumatol. 1994;21:33–6.
   PubMed Web of Science ®Google Scholar
• Yoshizawa H, Kudo H, Iwano K, Yamada A, Aikawa T, Mi-yamoto Y, et al. Causes of death in patients with rheumatoid arthritis-analysis of 117 cases for 13 years. Ryumachi. 1990; 30:255–63.
   Google Scholar
• Shinomiya F, Mima N, Nanba K, Tani K, Nakano S, Egawa H, et al. Life expectancies of Japanese patients with rheumatoid arthritis: a review of deaths over a 20-year period. Mod Rheu-matol. 2008;18:165–9.
   PubMed Web of Science ®Google Scholar
• Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44–8.
   Google Scholar
• Matsuda Y, Singh G, Yamanaka H, Tanaka E, Urano W, Tan-iguchi A, et al. Validation of a Japanese version of the Stanford Health Assessment Questionnaire in 3,763 patients with rheu-matoid arthritis. Arthritis Rheum. 2003;49: 784–8.
   Google Scholar
• Yamanaka H, Inoue E, Singh G, Tanaka E, Nakajima A, Tan-iguchi A, et al. Improvement of disease activity of rheumatoid arthritis patients from 2000 to 2006 in a large observational cohort study IORRA in Japan. Mod Rheumatol. 2007;17: 283–9.
   Google Scholar
• Nakajima A, Inoue E, Shidara K, Hoshi D, Sato E, Seto Y, et al. Standard treatment in daily clinical practice for early rheumatoid arthritis improved disease activity from 2001 to 2006. Mod Rheumatol. 2011;21:594–7.
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.
   PubMed Web of Science ®Google Scholar
• Kauppi M, Sokka T, Hannonen P. Survey nonresponse is associated with increased mortality in patients with rheumatoid arthritis and in a community population. J Rheumatol. 2005;32:807–10.
   Google Scholar
• Jacobsson LT, Turesson C, Gulfe A, Kapetanovic MC, Petersson IF, Saxne T, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol. 2005;32:1213–8.
   PubMed Web of Science ®Google Scholar
• Westlake SL, Colebatch AN, Baird J, Curzen N, Kiely P, Quinn M, et al. Tumour necrosis factor antagonists and the risk of cardio-vascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford). 2011;50:518–31.
   PubMed Web of Science ®Google Scholar
• Bongartz T, Nannini C, Medina-Velasquez YF, Achenbach SJ, Crowson CS, Ryu JH, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2010;62:1583–91.
   Google Scholar
• Dixon WG, Hyrich KL, Watson KD, Lunt M, Symmons DP. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2010;69:1086–91.
   Google Scholar